Futu Insights news on July 7, this Thursday $RAINMED-B (02297.HK)$The company announced the issuance of 23.348 million shares, priced at HKD 6.24 per share, with each lot containing 1,000 shares. The stock is expected to be listed on July 8.
In the public offering tranche, RheoMed Biotech-B received a 6.35x subscription. The final number of shares allocated to the public offering was 2.336 million, accounting for approximately 10% of the total offering (before any exercise of over-allotment options). A total of 4,032 valid applications were received, with a lottery success rate of 20.01% for one lot.
Additionally, the international offering has been oversubscribed. The final number of shares in the international offering is 21.012 million, representing approximately 90% of the total offering (before any exercise of over-allotment options). Futu Insights compiled the relevant data as shown in the table below.
According to the prospectus, RheoMed Biotech-B is a Chinese medical device company established in 2014. Its core products, the caFFR system and the caIMR system, are mainly used to evaluate the severity of myocardial ischemia caused by coronary artery stenosis and microvascular dysfunction.
RheoMed Biotech-B is one of the first companies in China to commercially launch an angiography-based FFR system. Its caFFR system has become the leading domestic FFR measurement product, boasting an accuracy rate of 95.7%, the highest among domestic FFR measurement products.
The company is currently developing its caIMR system, which is the world's only system that has completed confirmatory clinical trials for mic...